Fig. 3From: Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patientsCost effectiveness plane and cost effectiveness acceptability curve—DTG + TDF/3TC vs LPV/r + TDF/3TCBack to article page